Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Grows By 286.7%

Entera Bio Ltd. (NASDAQ:ENTX) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 1,150,114 shares, an increase of 286.7% from the July 15th total of 297,452 shares. Based on an average daily volume of 7,664,901 shares, the short-interest ratio is presently 0.2 days. Currently, 2.6% of the shares of the company are short sold.

Entera Bio Price Performance

Shares of ENTX stock traded down $0.03 on Friday, hitting $2.84. 134,880 shares of the company’s stock were exchanged, compared to its average volume of 1,150,819. The company has a 50 day moving average of $1.98 and a 200 day moving average of $1.53. The stock has a market cap of $492.41 million, a P/E ratio of -8.13 and a beta of 1.38. Entera Bio has a 12 month low of $0.91 and a 12 month high of $4.20.

Entera Bio (NASDAQ:ENTX) last issued its earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Sell-side analysts predict that Entera Bio will post -0.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ENTX has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research note on Wednesday, June 24th. Wall Street Zen raised Entera Bio to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $9.00.

Institutional Trading of Entera Bio

A number of hedge funds and other institutional investors have recently modified their holdings of ENTX. Citadel Advisors LLC lifted its stake in shares of Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after acquiring an additional 28,322 shares during the last quarter. HighTower Advisors LLC raised its position in Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Entera Bio by 22.2% during the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock valued at $210,000 after purchasing an additional 19,601 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock valued at $144,000 after buying an additional 43,536 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its holdings in Entera Bio by 5.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock valued at $1,157,000 after buying an additional 29,629 shares during the last quarter. Institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.